Back to search

Article

Gastrointestinal and Genitourinary Toxicity Profiles of Metformin Versus Placebo in Men With Prostate Cancer Receiving Pelvic Radiotherapy: Interim Toxicity Results of a Double-blinded, Multicenter, Phase II Randomized Controlled Trial

2021-02-23

Abstract excerpt

<title>Abstract</title> <p>Androgen deprivation therapy (ADT) used for prostate cancer (PCa) management is associated with metabolic and anthropometric toxicity. Metformin given concurrent to ADT is hypothesized to counteract these changes. This planned interim analysis reports the gastrointestinal and genitourinary toxicity profiles of PCa patients receiving ADT and prostate/pelvic radiotherapy plus metformin ve...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ce4e16ca-7b6b-5818-a217-1fb60acbdd36
DOI
10.21203/rs.3.rs-237354/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Gastrointestinal and Genitourinary Toxicity Profiles of Metformin Versus Placebo in Men With Prostate Cancer Receiving Pelvic Radiotherapy: Interim Toxicity Results of a Double-blinded, Multicenter, Phase II Randomized Controlled TrialDOI 10.21203/rs.3.rs-237354/v1
Report prepared for the Health Technology Assessment panel of the NHS Executive on the diagnosis, management, treatment and costs of prostate cancer in England and Wales.Semantic proximity
Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer.Semantic proximity
A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer.Semantic proximity
State-of-the-art prostate cancer treatment and research. A report from the Cancer Institute of New Jersey.Semantic proximity
Reduced risk of prostate cancer in a cohort of Lithuanian diabetes patientsSemantic proximity
Prostate cancer treatment – China's perspectiveSemantic proximity
Apigenin-Melatonin: a novel prostate cancer Radiation SensitizerSemantic proximity
Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial.Semantic proximity
Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09).Semantic proximity
Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study.Semantic proximity
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.Semantic proximity
Anti-prostate cancer activity of a β-carboline alkaloid enriched extract from Rauwolfia vomitoriaSemantic proximity
Select a neighboring publication to make it the new centre.